Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review

Diabetes & Metabolism, Volume 50, Issue 2, 2024 Mar, Article 101508 | Scheen, André J.Highlights•Patients with type 2 diabetes are at increased risk of atherosclerotic cardiovascular disease and heart failure. •New antihyperglycaemic agents, both GLP-1RAs and SGLT2is, have proven their efficacy in reducing the risk of cardiovascula… Source

You may also like...